acute myeloid leukemia

NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research Published Latest Acute Myeloid Leukemia Diagnostics Market Study by in-depth analysis of the current scenario, the…

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant…

Pune, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global acute myeloid leukemia market is expected to clock US$ 4.31 billion by…

New York, USA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape…

Biomarkers & Prevention, suggest a gap in critical data surveillance needs to be examined to further understand what is impacting long-term survivorship for AYAs. …

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia, accounting for roughly 5% to 15% of cases. What makes…

MONMOUTH JUNCTION, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced…

Acute myeloid leukemia (AML) is an aggressive cancer originating from blood cells. When immature blood cells in the bone marrow acquire certain aberrations in their genome they can become…

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative…

Allogeneic hematopoietic cell transplantation (HCT) is appropriate for most older patients with acute myeloid leukemia (AML),…